The recommended dose of RECONCILE chewable tablets is 1-2 mg/kg (0.5-0.9 mg/lb) administered once daily, in conjunction with a behavior modification plan. A typical behavior modification plan consists of the pet owner implementing standard training techniques based on principles such as rewarding appropriate behavior; coming and going in a manner that does not elicit inappropriate responses from the dog; and teaching the dog to be content while alone.
Table 1: Recommended Dose of RECONCILE Chewable Tablets
Dog Weight
No. of
Tablets/day
Tablet Strength
(mg)
(lb)
(kg)
8.8 -17.6
4.0 – 8.0
1
8
17.7 - 35.2
8.1 –16.0
1
16
35.3 - 70.4
16.1 – 32.0
1
32
70.5 - 140.8
32.1 – 64.0
1
64
The effectiveness and safety of RECONCILE chewable tablets was demonstrated in a field study in client-owned dogs (see EFFECTIVENESS and ADVERSE REACTIONS). At the end of the 8-week study, 73% of dogs treated with RECONCILE chewable tablets showed significant improvement (p=0.010), as compared to behavior modification alone (51%). During the course of therapy, 42% of dogs showed improvement within the first week, which was significantly greater (p=0.005) than with behavior modification alone (18%). The patient's response to therapy should be monitored. If no improvement is noted within 8 weeks, case management should be reevaluated.
The effectiveness and clinical safety of RECONCILE chewable tablets for long-term use (i.e. for more than 8 weeks) has not been evaluated. RECONCILE chewable tablets were evaluated at the recommended label dose for one year in a laboratory safety study in dogs (see ANIMAL SAFETY).
Professional judgment should be used in monitoring the patient's response to therapy to determine the need to continue treatment with RECONCILE chewable tablets beyond 8 weeks. To discontinue therapy, it is not necessary to taper or reduce doses because of the long half-life of this product. Continued behavioral modification is recommended to prevent recurrence of the clinical signs.
RECONCILE chewable tablets are readily consumed by dogs or can be administered like other tablet medications, and can be given with or without food. Professional discretion should be used in determining the need for dose reduction in the event of a possible adverse reaction. Approximately half of patients tolerate a return to the previous dose after 1-2 weeks on a reduced schedule (see ADVERSE REACTIONS). If a dose is missed, the next scheduled dose should be administered as prescribed. Do not increase or double the dose.
